"Emerging Drug Discovery Targets" summarizes the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition explores recent advances in the use of siRNA technology in oncology, new molecular targets for the treatment of diabetes and advances in the development of GSK-3 inhibitors. Recent preselected press releases are also highlighted and as usual new licensing opportunities, breaking publications and new industry reports are all identified.
Proof of concept studies have accumulated supporting the targeting of glycogen synthase kinase-3 (GSK-3) for the treatment of diabetes and CNS conditions. Now inhibitors are emerging as therapeutic candidates
"Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity" represents a cutting edge analysis of why and how ghrelin should be targeted for the identification of new therapies for obesity
â€˜Drug Rep Successâ€™ is the most complete of the numerous books published in the last 18 months or so that purport to offer guidance to the wannabe Medical Sales Rep and enhance the productivity of the established rep.
As businesses start to get ready for the next up-cycle, new Names Identities and Images are underway. Big time branding failures and silly naming of the recent past taught marketers some key lessons. Here, is a quick guide to test any Name Identity in use or being planned for the upswing.
Pharmiweb's first online recruitment training day saw a group of seasoned recruiters and HR professionals studying and workshopping ideas for more effective online recruitment in a one day session.
The medical community is quickly evolving its understanding of menopause. Following the abrupt, early halt to the HRT portion of the Women's Health Initiative last July, due to findings that Hormone Replacement Therapy's risks outweighed its benefits, headlines now read
Nancy Lonsdorf M.D.
Tim Taylor, Chief Business Development Officer at McLaren, looks at the role that IT can play in the improvement of process automation and control to positively benefit business strategies. An effective information management strategy can support companies, rather than hamper them, enabling them to build an organisation and systems that can manage extended global business applications in a compliant and efficient fashion.
As it aims to correct the underlying genetic defects in human disease rather than just focusing on symptoms, gene therapy offers the potential for actual cures. However, several technical and safety issues have hampered progress.
Dr Faiz Kermani
Some of the worldâ€™s leading drugs, such as Bristol-Myers Squibbâ€™s pravastatin for high cholesterol, TAPâ€™s lansoprazole and Daiichiâ€™s levofloxacin were discovered in Japanese laboratories. With this history of important drug research there is keen interest in biotechnology.
Dr Faiz Kermani
The increase in life expectancy coupled with a decreasing birth rate will place considerable pressure on governments and healthcare providers. Governments are having to reassess how they allocate their healthcare spending given that on average, the over 65s require four times as much healthcare resources as younger people.
Dr Faiz Kermani
Research towards the development of ion channel modulators is booming. One exciting target is the Kv1.3 voltage activated potassium channel. Expressed by human T lymphocytes Kv1.3 is involved in proliferation and cytokine secretion. Animal studies have established Kv1.3 as a target for the unmet multiple sclerosis (MS) market. Further key proof of concept data has now emerged demonstrating the selective expression of this channel in myelin-reactive effector memory T cells from MS patients
Pharma NewsBytes is LeadDiscovery's summary of news items released from the pharmaceutical and biotech sector over the previous two weeks. This week we feature the FDA's backing of the statin, Crestor; a new agreement based on the development of HDAC inhibitors which could leed to imporved cancer therapeutics; a novel and highly promising approach to metabolic disease announced by Roche; emerging clinical data on what appears to be an effective treatment of primary liver cancer and more.....
Faced with rising costs, shortened product lifecycles and an increasing reliance on blockbuster drugs, pharmaceutical companies are turning towards innovative marketing campaigns and new channels to reach an increasingly demanding consumer audience. Offering particular potential, campaign management solutions are being introduced to establish profitable interactions with large numbers of consumers across multiple channels.
Although elderly people have a higher incidence of the four major cancers than any other age group, there is a fundamental lack of knowledge regarding the treatment of this demographic, resulting in their under-treatment. Commercial opportunity therefore awaits any pharmaceutical company able to target the development of strategies aimed specifically at elderly patients.
The pharmaceutical industry is currently sinking considerable resources into the treatment of autoimmune disorders. One new candidate target is the histone deacetylase, HDAC7, reviewed in LeadDiscoveryâ€™s Target of the Month for July. HDAC7 inhibits Nur77 expression, a key regulator of T cell receptor mediated T cell apoptosis. Blocking HDAC7 can potentialy enhance apoptosis of autoreactive T cells and HDAC7 inhibitors may therefore be candidate treatments of autoimmune disorders.
Biogen and Idec Pharmaceuticals are set to merge in a stock-for-stock transaction valued at over $6.6 billion following announcements made earlier this week. The deal will create the third largest biotech firm in the world, yet Wall Street has so far appeared unimpressed by the deal. Even individual analysts seem to be disagreeing as to the strategic sense of the partnership.
At every stage of the R&D process, the companies must evaluate the time, logistics, expense and expertise that they can allocate. This also entails knowing when to rely on in-house capabilities and wh
Dr Faiz Kermani
Uncontrolled proliferation is a common feature of malignant cells. Proliferation correlates with a nuclear protein known as Ki-67. Researchers have now shown that an antisense oligonucleotide against
To mark the American Society of Clinical Oncology's 2003 conference, LeadDiscovery has launched The Oncology Collection. The Oncology Collection groups all of LeadDiscovery's oncology services in one
Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, wi
Eli Lilly and Company is set to launch Cymbalta into the depression and stress urinary incontinence markets in mid-2003. Datamonitor analyzes whether the company most synonymous with the antidepressan
Switzerland has been a major force in the development of new medicines for over a century. Around 5% of current global pharmaceutical R&D is attributable to Swiss companies.
Larry Hughes and Dr Faiz Kermani
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her